Header Logo

Connection

William Hildebrand to HLA-A Antigens

This is a "connection" page, showing publications William Hildebrand has written about HLA-A Antigens.
Connection Strength

2.514
  1. Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res. 2008 Apr; 7(4):1445-57.
    View in: PubMed
    Score: 0.301
  2. Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods. 2006 Jul 31; 314(1-2):38-53.
    View in: PubMed
    Score: 0.266
  3. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. Biochemistry. 2005 Sep 20; 44(37):12491-507.
    View in: PubMed
    Score: 0.253
  4. Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry. 2004 Nov 23; 43(46):14852-63.
    View in: PubMed
    Score: 0.239
  5. Non-conservative substitutions distinguish previously uncharacterized HLA-A molecules. Tissue Antigens. 2001 Feb; 57(2):95-102.
    View in: PubMed
    Score: 0.183
  6. Precision genotyping of human leukocyte antigen-A, -B and -C loci via direct DNA sequencing. Methods Mol Biol. 2001; 156:129-42.
    View in: PubMed
    Score: 0.182
  7. Characterization of an HLA-A26 serologic variant. Immunogenetics. 1998 Jul; 48(2):152-5.
    View in: PubMed
    Score: 0.153
  8. Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late. J Immunol. 2016 05 15; 196(10):4263-73.
    View in: PubMed
    Score: 0.132
  9. The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. J Immunol. 2016 Feb 15; 196(4):1480-7.
    View in: PubMed
    Score: 0.129
  10. Molecular characterization of HLA-A*6803. Immunogenetics. 1996; 45(1):78-9.
    View in: PubMed
    Score: 0.129
  11. An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011 Jun 01; 186(11):6607-16.
    View in: PubMed
    Score: 0.093
  12. Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires. J Immunol. 2011 Feb 01; 186(3):1575-88.
    View in: PubMed
    Score: 0.091
  13. Amyloid precursor-like protein 2 association with HLA class I molecules. Cancer Immunol Immunother. 2009 Sep; 58(9):1419-31.
    View in: PubMed
    Score: 0.080
  14. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007 Jan 10; 318(1-2):47-58.
    View in: PubMed
    Score: 0.068
  15. Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood. 2002 May 01; 99(9):3360-6.
    View in: PubMed
    Score: 0.050
  16. Disparate binding of chaperone proteins by HLA-A subtypes. Immunogenetics. 2002 Feb; 53(10-11):830-4.
    View in: PubMed
    Score: 0.049
  17. Sequence-based typing of HLA class I alleles in Alaskan Yupik Eskimo. Hum Immunol. 2001 Jun; 62(6):639-44.
    View in: PubMed
    Score: 0.047
  18. Characterization of baboon class I major histocompatibility molecules. Implications for baboon-to-human xenotransplantation. Transplantation. 1996 Apr 15; 61(7):989-96.
    View in: PubMed
    Score: 0.033
  19. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One. 2010 Dec 13; 5(12):e15343.
    View in: PubMed
    Score: 0.023
  20. HLA antigens, alleles and haplotypes among the Yup'ik Alaska natives: report of the ASHI Minority Workshops, Part II. Hum Immunol. 2002 Jul; 63(7):614-25.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.